Showing 1 posts of 1 posts found.
Astellas Pharma has agreed to buy Ocata, a firm specialising in cloning and embryonic stem cell therapies, for $379 million. …
NICE recommends daratumumab quadruplet for newly diagnosed multiple myeloma
AstraZeneca’s Trixeo approved in EU for asthma
Amplio reports early human data for novel methotrexate approach in rheumatoid arthritis
Survodutide delivers up to 13.1% weight loss in phase 3 obesity and diabetes trial
ESTEVE CDMO adds $17.5m to Illinois expansion